OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Thigpen on Comparing Treatments in Ovarian Cancer

October 7th 2013

James "Tate" T. Thigpen, MD, Professor of Medicine, Director, Division of Medical Oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.

Dr. Ruff on Prior Bevacizumab in the VELOUR Trial

October 4th 2013

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

Dr. Kudchadkar on BRAF and MEK Inhibitors in Melanoma

October 4th 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

Dr. Zujewski Discusses Breast Cancer Drug Development

October 3rd 2013

Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.

Dr. Markman on Targets for the Treatment of Ovarian Cancer

September 30th 2013

Maurie Markman, MD, from the Cancer Treatment Centers of America, discusses the discovery of mutations and targets in ovarian cancer and the current progress being made in the development of a "breakthrough" agent for ovarian cancer.

Dr. Hudis on the Optimism Surrounding Immunotherapy

September 27th 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Dr. Novello on the Gray Areas in Lung Cancer Care

September 27th 2013

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.

Dr. Brahmer Discusses Managing Immunotherapy AEs

September 26th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Dr. Nielsen on the Pros and Cons of the Ki67 Assay

September 26th 2013

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.

Dr. Carvajal on the Design of a Trial in Uveal Melanoma

September 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.

Dr. Pass on Blood-Based Markers in Lung Cancer

September 25th 2013

Harvey I. Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, discusses blood-based markers in lung cancer.

Dr. Albain on Staging and Biology in Breast Cancer

September 24th 2013

Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses staging versus biology in breast cancer.

Dr. Sosman on the Mechanism of Action of Ipilimumab

September 24th 2013

Jeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.

Dr. Mitchell on Survival and Safety of the VELOUR Trial

September 23rd 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.

Dr. Scagliotti on Treating EGFR-Mutated Tumors with Afatinib

September 23rd 2013

Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.

Dr. Woyach on the Role of BTK in CLL

September 20th 2013

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL).

Dr. Liu on the Limitations of Radiology in Breast Cancer

September 20th 2013

Minetta Liu, MD, breast cancer specialist, Mayo Clinic, Rochester, Minnesota, discusses the limitations of radiology in metastatic breast cancer treatment.

Dr. Shore Comments on the Approval of Radium-223

September 19th 2013

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

Dr. Herbst on Targeting PD-1 and PD-L1 in Lung Cancer

September 19th 2013

Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.